EP0861238A4 - Hexahydro-5-imino-1,4-heteroazepinderivate als inhibitoren von stickstoffoxid-sythase - Google Patents

Hexahydro-5-imino-1,4-heteroazepinderivate als inhibitoren von stickstoffoxid-sythase

Info

Publication number
EP0861238A4
EP0861238A4 EP96937836A EP96937836A EP0861238A4 EP 0861238 A4 EP0861238 A4 EP 0861238A4 EP 96937836 A EP96937836 A EP 96937836A EP 96937836 A EP96937836 A EP 96937836A EP 0861238 A4 EP0861238 A4 EP 0861238A4
Authority
EP
European Patent Office
Prior art keywords
heteroazepine
hexahydro
imino
inhibitors
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96937836A
Other languages
English (en)
French (fr)
Other versions
EP0861238A1 (de
Inventor
Charles G Caldwell
William K Hagmann
Malcolm Maccoss
Shrenik K Shah
Kothandaraman Shankaran
Karla L Furman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605162.8A external-priority patent/GB9605162D0/en
Priority claimed from GBGB9605700.5A external-priority patent/GB9605700D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0861238A1 publication Critical patent/EP0861238A1/de
Publication of EP0861238A4 publication Critical patent/EP0861238A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96937836A 1995-11-01 1996-10-28 Hexahydro-5-imino-1,4-heteroazepinderivate als inhibitoren von stickstoffoxid-sythase Withdrawn EP0861238A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US717295P 1995-11-01 1995-11-01
US7172P 1995-11-01
US901295P 1995-12-21 1995-12-21
US9012P 1995-12-21
GBGB9605162.8A GB9605162D0 (en) 1996-03-12 1996-03-12 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9605162 1996-03-12
GBGB9605700.5A GB9605700D0 (en) 1996-03-19 1996-03-19 Hexahydro-5-imino,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9605700 1996-03-19
PCT/US1996/017447 WO1997016430A1 (en) 1995-11-01 1996-10-28 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases

Publications (2)

Publication Number Publication Date
EP0861238A1 EP0861238A1 (de) 1998-09-02
EP0861238A4 true EP0861238A4 (de) 2000-03-01

Family

ID=27451425

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937836A Withdrawn EP0861238A4 (de) 1995-11-01 1996-10-28 Hexahydro-5-imino-1,4-heteroazepinderivate als inhibitoren von stickstoffoxid-sythase

Country Status (5)

Country Link
EP (1) EP0861238A4 (de)
JP (1) JP3188715B2 (de)
AU (1) AU700078B2 (de)
CA (1) CA2234641A1 (de)
WO (1) WO1997016430A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897912A1 (de) * 1993-10-21 1999-02-24 G.D. Searle & Co. Amidinoderivate als NO-Synthetase-Inhibitoren
BR9608012A (pt) * 1995-04-20 1999-01-05 Searle & Co Agentes de amidino cíclicos úteis como inbidores da sintase do óxido nítrico
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
CA2333691A1 (en) 1998-06-10 1999-12-16 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
SE9901530D0 (sv) * 1999-04-28 1999-04-28 Astra Pharma Prod Novel compounds
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
EP2090578A1 (de) 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Arylamid-Diazepinopyrimidon-Derivate zur Behandlung von neurodegenerativen Erkrankungen verursacht durch eine abnormale GSK3-beta-Aktivität
EP2085399A1 (de) 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Arylamidoxazepinopyrimidon-Derivate
EP2085400A1 (de) 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Heteroarylamid-Oxazepinopyrimidon-Derivate
EP2090579A1 (de) 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Heteroarylamiddiazepinopyrimidon-Derivate
EP2138488A1 (de) 2008-06-26 2009-12-30 sanofi-aventis 4-(Pyridin-4-yl)-1H-[1,3,5]Triazin-2-one-Verbindungen als GSK3-beta Hemmer zur Behandlung neurodegenerative Erkrankungen
EP2138495A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate
EP2138485A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte N-Oxid-Pyrazin-Derivate
EP2138493A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidon-Derivate
EP2138492A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidin-4-one-Derivate
EP2138498A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte trizyklische Derivate gegen neurodegenerative Erkrankungen
EP2138494A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Alkylpyrimidin-4-one-Derivate
EP4065567A1 (de) * 2019-11-26 2022-10-05 Gilead Sciences, Inc. Verfahren und zwischenprodukte zum herstellen von mcl1-hemmern

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
FR1508536A (fr) * 1966-01-17 1968-01-05 American Cyanamid Co Nouveau procédé pour la préparation des 11-tert-aminodibenz[b, f][1, 4]oxazépines et thiazépines
FR2292479A1 (fr) * 1974-11-26 1976-06-25 Lilly Industries Ltd Derives de benzodiazepine
EP0129692A2 (de) * 1983-05-18 1985-01-02 Hoechst-Roussel Pharmaceuticals Incorporated Dibenzodiazepin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
WO1995011231A1 (en) * 1993-10-21 1995-04-27 G. D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
WO1996014844A1 (en) * 1994-11-15 1996-05-23 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES436126A1 (es) * 1974-11-29 1977-04-01 Sandoz Ag Un procedimiento para la produccion de derivados de 2, 3-di-hidro-1h-1, 4 diazepina.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
FR1508536A (fr) * 1966-01-17 1968-01-05 American Cyanamid Co Nouveau procédé pour la préparation des 11-tert-aminodibenz[b, f][1, 4]oxazépines et thiazépines
FR2292479A1 (fr) * 1974-11-26 1976-06-25 Lilly Industries Ltd Derives de benzodiazepine
EP0129692A2 (de) * 1983-05-18 1985-01-02 Hoechst-Roussel Pharmaceuticals Incorporated Dibenzodiazepin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
WO1995011231A1 (en) * 1993-10-21 1995-04-27 G. D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
WO1996014844A1 (en) * 1994-11-15 1996-05-23 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A. BAUER ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, no. 9, 1973, WASHINGTON US, pages 1011 - 1014, XP002126762 *
AMBROGI V ET AL: "Studies on annulated 1,4-benzothiazines and 1,5-benzothiazepines. IX. Imidazo[2,1-d][1,5]benzothiazepines: synthesis and in vitro benzodiazepine receptor affinity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA,FR,EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, vol. 30, no. 5, pages 429-437, XP004040163, ISSN: 0223-5234 *
C. CORRAL ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 14, no. 6, 1977, PROVO US, pages 985 - 988, XP002126761 *
CHEMICAL ABSTRACTS, vol. 92, no. 17, 28 April 1980, Columbus, Ohio, US; abstract no. 146818, ARYA, VISHWA PRAKASH: "Heterocyclic compounds having hypoglycemic properties" XP002126763 *
CHEMICAL ABSTRACTS, vol. 94, no. 9, 2 March 1981, Columbus, Ohio, US; abstract no. 65731, ALESHINA, G. A. ET AL: "11-Substituted-5H-dibenzo-[b,e][1,4]-diazepines" XP002126764 *
D. KORAKAS ET AL., SYNTHESIS, vol. 2, 1994, pages 164 - 166, XP002126757 *
H.A. HAMMOUDA ET AL., EGYPT. J. CHEM., vol. 30, no. 3, 1987, pages 239 - 247, XP002126759 *
K. TAGAKI ET AL., SYNTHESIS, vol. 4, 1987, pages 379 - 381, XP002126760 *
R. CAUJOLLE ET AL., EUR. J. MED. CHEM., vol. 28, no. 1, 1993, pages 29 - 35, XP002126758 *
See also references of WO9716430A1 *

Also Published As

Publication number Publication date
JP3188715B2 (ja) 2001-07-16
AU7528796A (en) 1997-05-22
JPH11501327A (ja) 1999-02-02
AU700078B2 (en) 1998-12-17
CA2234641A1 (en) 1997-05-09
EP0861238A1 (de) 1998-09-02
WO1997016430A1 (en) 1997-05-09

Similar Documents

Publication Publication Date Title
EP0861238A4 (de) Hexahydro-5-imino-1,4-heteroazepinderivate als inhibitoren von stickstoffoxid-sythase
AU4149696A (en) Substituted heterocycles as inhibitors of nitric oxide synthase
HUP9800634A3 (en) P-amidino-benzylamide derivatives as thrombin inhibitors, intermediates and use thereof
AU6419296A (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU4515696A (en) Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
AU4515896A (en) Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU6718494A (en) 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
AU2747395A (en) Substituted oxime derivatives useful as pde iv inhibitors
PL334368A1 (en) Inhibitors of nitrogen oxide synthase
PL323470A1 (en) Application of n-propargil-1-amidoindane (r)-enantionmer, its salts and compositions containing same
IS5053A (is) 6-Fenýlpýridýl-2-amín afleiður nytsamlegar sem nituroxíð sýntasa tálmar
AU7705694A (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
PL329153A1 (en) Derivatives of pyrrolopyrolone as inhibitors of neutropil elastase
ZA969221B (en) Indolealkyl derivatives of benzodioxanmethylamine.
AU5652698A (en) (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
AU7570996A (en) Quinoline derivatives as type iv phosphodiesterase inhibitors
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use
ZA975986B (en) N-alkoxyadenine derivatives acting as cytokine inhibitors.
AU3901393A (en) Biphenylylquinuclidine derivatives as squalene synthase inhibitors
IL129035A0 (en) 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU7394394A (en) 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors
AU1841195A (en) 1-beta -methyl-carbapenem, compositions containing same and methods of use
IL132678A0 (en) Amidine derivatives as inhibitors of nitric oxide synthase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000118

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20001130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020319